Dimensional Fund Advisors LP Cuts Stake in Haleon plc (NYSE:HLN)

Dimensional Fund Advisors LP lowered its stake in shares of Haleon plc (NYSE:HLN) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 754,364 shares of the company’s stock after selling 48,334 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Haleon were worth $7,197,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company’s stock valued at $1,038,217,000 after acquiring an additional 3,909,545 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the period. Envestnet Asset Management Inc. lifted its stake in Haleon by 0.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company’s stock valued at $72,793,000 after purchasing an additional 58,444 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Haleon by 18.3% in the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock valued at $57,382,000 after purchasing an additional 930,701 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Haleon during the fourth quarter valued at $42,193,000. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on HLN. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Barclays restated an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Morgan Stanley upgraded shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 target price for the company in a research note on Friday. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Haleon Stock Performance

Shares of HLN opened at $10.75 on Monday. Haleon plc has a 52-week low of $8.24 and a 52-week high of $10.85. The stock’s 50-day simple moving average is $10.20 and its 200 day simple moving average is $9.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $48.48 billion, a price-to-earnings ratio of 31.62, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Research analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.